{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T01:39:04Z","timestamp":1790905144681,"version":"4.1.0"},"reference-count":84,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,7,1]],"date-time":"2010-07-01T00:00:00Z","timestamp":1277942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2010,7]]},"DOI":"10.1016\/j.pharma.2010.04.004","type":"journal-article","created":{"date-parts":[[2010,6,20]],"date-time":"2010-06-20T20:24:51Z","timestamp":1277065491000},"page":"218-232","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Impact actuel des produits naturels sur la d\u00e9couverte de nouveaux m\u00e9dicaments anticanc\u00e9reux"],"prefix":"10.1016","volume":"68","author":[{"given":"C.","family":"Monneret","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharma.2010.04.004_bib1","first-page":"3","article-title":"Mother Nature's gifts to diseases of man: the impact of natural products on anti-infective, anticholestemics and anticancer drug discovery","volume":"65","author":"Butler","year":"2008","journal-title":"Prog Drug Res"},{"key":"10.1016\/j.pharma.2010.04.004_bib2","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1039\/b514294f","article-title":"Natural products to drugs: natural product-derived compounds in clinical trial","volume":"25","author":"Butler","year":"2008","journal-title":"Natural Product Reports"},{"key":"10.1016\/j.pharma.2010.04.004_bib3","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1021\/cr900019j","article-title":"Impact of natural products on developing new anti-cancer agents","volume":"109","author":"Cragg","year":"2009","journal-title":"Chem Rev"},{"key":"10.1016\/j.pharma.2010.04.004_bib4","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.bcp.2008.12.013","article-title":"Ready for a comeback of natural products in oncology","volume":"77","author":"Bailly","year":"2009","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.pharma.2010.04.004_bib5","doi-asserted-by":"crossref","first-page":"3975","DOI":"10.1021\/jo800239a","article-title":"A natural love of natural products","volume":"73","author":"Kingson","year":"2008","journal-title":"J Org Chem"},{"key":"10.1016\/j.pharma.2010.04.004_bib6","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1126\/science.276.5313.734","article-title":"A molecular view of microbial diversity and the biosphere","volume":"276","author":"Pace","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.pharma.2010.04.004_bib7","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/nrd2487","article-title":"Drug development from marine natural products","volume":"8","author":"Molinski","year":"2009","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.pharma.2010.04.004_bib8","first-page":"1","article-title":"An interview with David Newman","volume":"6","author":"Glaser","year":"2008","journal-title":"Assay Drug Develop Technol"},{"key":"10.1016\/j.pharma.2010.04.004_bib9","first-page":"111","article-title":"Marine pharmaceuticals. Past, present, future","volume":"219","author":"Fenical","year":"2006","journal-title":"Oceanography"},{"key":"10.1016\/j.pharma.2010.04.004_bib10","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/00001813-200308000-00001","article-title":"Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin","volume":"14","author":"van Kesteren Ch","year":"2003","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.pharma.2010.04.004_bib11","unstructured":"Sigel MM, Wellham LL, Lichter W, Dudeck LE, Gargus JL, Lucas LH. Food-Drugs from the sea. Proceedings 1969."},{"key":"10.1016\/j.pharma.2010.04.004_bib12","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1021\/jo00302a006","article-title":"Antitumor tetrahydroisoquinoline alkaloids from the colonial ascidian Ecteinascidia turbinate","volume":"55","author":"Wright","year":"1990","journal-title":"J Org Chem"},{"key":"10.1016\/j.pharma.2010.04.004_bib13","doi-asserted-by":"crossref","first-page":"4512","DOI":"10.1021\/jo00302a007","volume":"55","author":"Rinehart","year":"1990","journal-title":"J Org Chem"},{"key":"10.1016\/j.pharma.2010.04.004_bib14","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1039\/b808331m","article-title":"Development of Yondelis (trabectedin, ET-743). A semisynthetic process solves the supply problem","volume":"26","author":"Cuevas","year":"2009","journal-title":"Natural Product Rep"},{"key":"10.1016\/j.pharma.2010.04.004_bib15","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1358\/dot.2009.45.6.1378934","article-title":"Mapping the literature: role of trabectedin as a new chemotherapy option in advanced pretreated soft tissue sarcoma","volume":"45","author":"Le Cesne","year":"2009","journal-title":"Drug Today"},{"key":"10.1016\/j.pharma.2010.04.004_bib16","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.ejca.2008.11.019","article-title":"Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer","volume":"45","author":"Sessa","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.pharma.2010.04.004_bib17","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1200\/JCO.2005.09.032","article-title":"Trabectedin for women with ovarian carcinoma after treatment with platinum and taxane fails","volume":"20","author":"Sessa","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pharma.2010.04.004_bib18","doi-asserted-by":"crossref","first-page":"13303","DOI":"10.1021\/bi960306b","article-title":"DNA-sequence and structure-selective alkylation of guanine N2\u00a0in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata","volume":"35","author":"Pommier","year":"1996","journal-title":"Biochemistry"},{"key":"10.1016\/j.pharma.2010.04.004_bib19","doi-asserted-by":"crossref","first-page":"6780","DOI":"10.1073\/pnas.97.12.6780","article-title":"Interference of transcriptional activation by the antineoplastic ecteinascidin-743","volume":"97","author":"Minuzzo","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharma.2010.04.004_bib20","first-page":"179","article-title":"Effect of ecteinascidin-743\u00a0on the interaction between DNA binding proteins and DNA","volume":"14","author":"Bonfanti","year":"1999","journal-title":"Anticancer Drug Des"},{"key":"10.1016\/j.pharma.2010.04.004_bib21","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1479-5876-4-3","article-title":"Adding pharmacogenomics to the development of new-marine derived anticancer agents","volume":"4","author":"Jimeno","year":"2006","journal-title":"J Transl Med"},{"key":"10.1016\/j.pharma.2010.04.004_bib22","first-page":"ECCO14","article-title":"Personalized therapy with trabectedin (Yondelis\u00ae) in advanced pre-treated sarcomas","volume":"5","author":"Jimeno","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.pharma.2010.04.004_bib23","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1158\/1535-7163.MCT-08-0848","article-title":"Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors","volume":"8","author":"Forni","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.pharma.2010.04.004_bib24","first-page":"789","article-title":"Novel microtubule-targeting agents \u2013 the epothilones","volume":"2","author":"Cheng","year":"2008","journal-title":"Biologics"},{"key":"10.1016\/j.pharma.2010.04.004_bib25","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1158\/1535-7163.MCT-08-0986","article-title":"Ixabepilone: targeting betaIII-tubulin expression in taxane-resistant malignancies","volume":"8","author":"Dumontet","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.pharma.2010.04.004_bib26","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1586\/14737140.8.8.1299","article-title":"Epothilones in breast cancer: current status and future directions","volume":"8","author":"Atzori","year":"2008","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.pharma.2010.04.004_bib27","first-page":"505","article-title":"Ixabepilone: a new chemotherapeutic option for refractory metastatic breast cancer","volume":"2","author":"Shannon Puhalla","year":"2008","journal-title":"Biologics"},{"key":"10.1016\/j.pharma.2010.04.004_bib28","doi-asserted-by":"crossref","first-page":"8123","DOI":"10.1158\/1078-0432.CCR-08-0025","article-title":"Synergistic antitumor activity of ixabepilone (BMS-247550) plus bevacizumab in multiple in vivo tumor models","volume":"14","author":"Lee","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pharma.2010.04.004_bib29","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1097\/CCO.0b013e32831270b0","article-title":"Application of epothilones in breast cancer therapy","volume":"20","author":"Cianfrocca","year":"2008","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.pharma.2010.04.004_bib30","first-page":"1182","article-title":"EPO-906 (Novartis)","volume":"6","author":"Galmarini","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.pharma.2010.04.004_bib31","doi-asserted-by":"crossref","first-page":"13157","DOI":"10.1073\/pnas.0804773105","article-title":"Therapeutic effect against human xenograft tumors in nude mice by the third generation microtubule stabilizing epothilones","volume":"105","author":"Chou","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharma.2010.04.004_bib32","first-page":"1359","article-title":"Sagopilone, a microtubule stabilizer for the potential treatment of cancer","volume":"10","author":"Galmarini","year":"2009","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.pharma.2010.04.004_bib33","doi-asserted-by":"crossref","first-page":"721","DOI":"10.7164\/antibiotics.28.721","article-title":"Rapamycin (AV-22, 989), a new antifungal antibiotic. 1. Taxonomy of the producing streptomycete and isolation of the active principle","volume":"28","author":"Vezina","year":"1975","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.pharma.2010.04.004_bib34","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1046\/j.1523-1755.2001.00460.x","article-title":"Rapamycin in transplantation, a review of the evidence","volume":"59","author":"Saunders","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharma.2010.04.004_bib35","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1126\/science.1715094","article-title":"Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast","volume":"253","author":"Heitman","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.pharma.2010.04.004_bib36","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/nri2546","article-title":"Immunoregulatory functions of m-TOR inhibition","volume":"9","author":"Thomson","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.pharma.2010.04.004_bib37","doi-asserted-by":"crossref","first-page":"6436","DOI":"10.1038\/sj.onc.1209886","article-title":"m-TOR and cancer therapy","volume":"25","author":"Easton","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.pharma.2010.04.004_bib38","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nrd2062","article-title":"Current development of m-TOR inhibitors as anticancer agents","volume":"5","author":"Faivre","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.pharma.2010.04.004_bib39","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s12094-010-0461-4","article-title":"Molecular basis for the treatment of renal cell carcinoma","volume":"12","author":"Su\u00e1rez","year":"2010","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.pharma.2010.04.004_bib40","doi-asserted-by":"crossref","first-page":"764s","DOI":"10.1158\/1078-0432.CCR-06-1975","article-title":"Opportunities and obstacles to combination targeted therapy in renal cell cancer","volume":"13","author":"Sosman","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pharma.2010.04.004_bib41","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma","volume":"27","author":"Hess","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pharma.2010.04.004_bib42","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1093\/jnci\/djp034","article-title":"Targeting m-TOR: something old, something new","volume":"101","author":"Graber","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.pharma.2010.04.004_bib43","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.pharma.2010.04.004_bib44","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0003-4509(05)82248-5","article-title":"A new anti-cancer fluorinated-agent derived from vinca alkaloids","volume":"63","author":"Jacquesy","year":"2005","journal-title":"Ann Pharm Fr"},{"key":"10.1016\/j.pharma.2010.04.004_bib45","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1038\/sj.bjc.6603118","article-title":"A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen","volume":"94","author":"Culine","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.pharma.2010.04.004_bib46","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s10637-006-6437-0","article-title":"Phase II study of vinflunine in patients with metastatic renal cell carcinoma","volume":"24","author":"Goldstein","year":"2006","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.pharma.2010.04.004_bib47","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1200\/JCO.2008.20.5534","article-title":"Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract","volume":"27","author":"Bellmunt","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pharma.2010.04.004_bib48","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1517\/14656566.9.6.1029","article-title":"Homoharringtonine for the treatment of chronic myelogenous leukemia","volume":"9","author":"Quint\u00e0s-Cardama","year":"2008","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.pharma.2010.04.004_bib49","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1517\/13543780903119167","article-title":"Larotaxel; broadening the road with new taxanes","volume":"18","author":"Metzger-Filho","year":"2009","journal-title":"Expert Opin Investig Drugs"},{"issue":"Suppl. 1","key":"10.1016\/j.pharma.2010.04.004_bib50","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1007\/s00280-003-0624-x","article-title":"Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms","volume":"52","author":"Senderowicz","year":"2003","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.pharma.2010.04.004_bib51","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1097\/CCO.0b013e3282f10a00","article-title":"Enzastaurin","volume":"19","author":"Ma","year":"2007","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.pharma.2010.04.004_bib52","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1158\/0008-5472.CAN-07-3195","article-title":"Enzastaurin, a protein kinase C beta inhibitor, suppresses signalling through the ribosomal S6\u00a0kinase and bad pathways and induces apoptosis in human gastric cancer cells","volume":"68","author":"Lee","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharma.2010.04.004_bib53","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1200\/JCO.2007.11.7960","article-title":"Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2\u00a0overexpressing breast cancer: a phase I dose-escalation study","volume":"25","author":"Modi","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pharma.2010.04.004_bib54","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.2174\/156802606777811979","article-title":"Using natural product inhibitors to validate Hsp90\u00a0as a molecular target in cancer","volume":"6","author":"Neckers","year":"2006","journal-title":"Curr Top Med Chem"},{"key":"10.1016\/j.pharma.2010.04.004_bib55","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1016\/j.bmc.2008.10.075","article-title":"Discovery and development of the anticancer agent, salinosporamide A (NPI-0052)","volume":"17","author":"Fenical","year":"2009","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.pharma.2010.04.004_bib56","first-page":"69","article-title":"Natural Products pharmaceuticals","volume":"9","author":"McCullagh","year":"2008","journal-title":"Drug Discov World Winter"},{"key":"10.1016\/j.pharma.2010.04.004_bib57","first-page":"22","article-title":"Combinatorial biosynthesis panning for pharmaceutical gold","volume":"2","author":"Bochart","year":"1999","journal-title":"Mod Drug Discov"},{"key":"10.1016\/j.pharma.2010.04.004_bib58","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1039\/a909079g","article-title":"Polyketide synthesis: a millenium review","volume":"18","author":"Staunton","year":"2001","journal-title":"Nat Prod Rep"},{"key":"10.1016\/j.pharma.2010.04.004_bib59","first-page":"829","article-title":"Ciblage de mol\u00e9cules antitumorales par les anticorps monoclonaux","volume":"87","author":"Monneret","year":"2000","journal-title":"Bull Cancer"},{"key":"10.1016\/j.pharma.2010.04.004_bib60","first-page":"1626","article-title":"Effet sur la leuc\u00e9mie L1210\u00a0de la souris d\u2019une combinaison par diazotation d\u2019A-m\u00e9thoprine et de \u03b3-globulines de hamsters porteurs de cette leuc\u00e9mie par h\u00e9t\u00e9rogreffe","volume":"246","author":"Math\u00e9","year":"1958","journal-title":"C R Acad Sci Paris"},{"key":"10.1016\/j.pharma.2010.04.004_bib61","doi-asserted-by":"crossref","first-page":"921","DOI":"10.4049\/jimmunol.111.3.921","article-title":"Selective cytotoxicity of hapten-substituted cells with an antibody enzyme conjugate","volume":"111","author":"Philpott","year":"1973","journal-title":"J Immunol"},{"key":"10.1016\/j.pharma.2010.04.004_bib62","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/256495a0","article-title":"Continous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"Kohler","year":"1975","journal-title":"Nature"},{"key":"10.1016\/j.pharma.2010.04.004_bib63","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/0002-9343(93)90062-T","article-title":"Monoclonal antibodies in cancer detection and therapy","volume":"94","author":"Goldenberg","year":"1993","journal-title":"Am J Med"},{"key":"10.1016\/j.pharma.2010.04.004_bib64","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1021\/ar00008a003","article-title":"Calicheamicins: discovery, structure, chemistry and interaction with DNA","volume":"24","author":"Lee","year":"1991","journal-title":"Acc Chem Res"},{"key":"10.1016\/j.pharma.2010.04.004_bib65","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1021\/bc0100206","article-title":"An anti-CD33\u00a0antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker","volume":"13","author":"Hamann","year":"2002","journal-title":"Bioconj Chem"},{"key":"10.1016\/j.pharma.2010.04.004_bib66","first-page":"1490","article-title":"Approval summary: gemtuzumab ozogamycin in relapsed acute myeloid leukemia","volume":"7","author":"Bros","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pharma.2010.04.004_bib67","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ejpb.2008.11.010","article-title":"Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect","volume":"71","author":"Maeda","year":"2009","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.pharma.2010.04.004_bib68","first-page":"127","article-title":"Immunoconjugates containing novel maytansinoids: promising anticancer drugs","volume":"52","author":"Chari","year":"1992","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharma.2010.04.004_bib69","doi-asserted-by":"crossref","first-page":"4392","DOI":"10.1021\/jm060319f","article-title":"Semisynthetic maytansine analogues for the targeted treatment of cancer","volume":"49","author":"Widdison","year":"2006","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharma.2010.04.004_bib70","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2174\/156800909788166484","article-title":"HER-2\u00a0signalling and inhibition in breast cancer","volume":"9","author":"Browne","year":"2009","journal-title":"Curr Cancer Drug Target"},{"key":"10.1016\/j.pharma.2010.04.004_bib71","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1177\/172460089901400104","article-title":"C-erbB-2\u00a0expression in primary breast cancer","volume":"14","author":"Tagliabue","year":"1999","journal-title":"Int J Biol Markers"},{"key":"10.1016\/j.pharma.2010.04.004_bib72","doi-asserted-by":"crossref","first-page":"9280","DOI":"10.1158\/0008-5472.CAN-08-1776","article-title":"Targeting HER2 -positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate","volume":"68","author":"Phillips","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharma.2010.04.004_bib73","series-title":"2009\u00a0ASCO Annual Meeting. Poster No. 1017","article-title":"A phase II study of trastuzumab-DM1 (T-DM1), a HER2\u00a0antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (MBC): Final results","author":"Vogel","year":"2009"},{"key":"10.1016\/j.pharma.2010.04.004_bib74","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1365-2141.2008.07000.x","article-title":"Targeting CD56\u00a0by the maytansinoid immunoconjugate IMGN901 (huN901-DM1): a potential therapeutic modality implication against natural killer\/T cell malignancy","volume":"141","author":"Ishitsuka","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.pharma.2010.04.004_bib75","series-title":"51th Annual Meeting of American Society of Hematology","article-title":"Study of IMGN901, used as monotherapy, in patients with heavily pre-treated cd56-positive multiple myeloma \u2013 a preliminary safety and efficacy","author":"Chanan-Khan","year":"2009"},{"key":"10.1016\/j.pharma.2010.04.004_bib76","first-page":"1","article-title":"The dolastatins. Forstschr","volume":"70","author":"Pettit","year":"1997","journal-title":"Chem Org Naturst"},{"key":"10.1016\/j.pharma.2010.04.004_bib77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/1573394052952456","article-title":"Targeting established tumor vasculature: a novel approach to cancer treatment","volume":"1","author":"Kelland","year":"2005","journal-title":"Curr Cancer Ther Rev"},{"key":"10.1016\/j.pharma.2010.04.004_bib78","first-page":"4205","article-title":"Phase II study of dolastatin-10\u00a0in patients with hormone refractory metastatic prostate adenocarcinoma","volume":"6","author":"Vaishampayan","year":"2000","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.pharma.2010.04.004_bib79","first-page":"1293","article-title":"Novel marine-derived anticancer agents; a phase I clinical, pharmacological, and pharmacodynamic study of dolastatin 10 (NSC 376128) in patients with advanced solid tumors","volume":"6","author":"Madden","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pharma.2010.04.004_bib80","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.cbpa.2009.03.023","article-title":"Potent antibody drug conjugates for cancer therapy","volume":"13","author":"Senter","year":"2009","journal-title":"Curr Opin Chem Biol"},{"key":"10.1016\/j.pharma.2010.04.004_bib81","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/nbt832","article-title":"Development of potent monoclonal antibody auristatin conjugates for cancer therapy","volume":"21","author":"Doronina","year":"2003","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.pharma.2010.04.004_bib82","first-page":"1458","article-title":"cAC10-vcMMAE, an anti-CD30-monomethylauristatin E conjugate with potent and selective antitumor activity","volume":"102","author":"Franscisco","year":"2003","journal-title":"Neoplasia"},{"key":"10.1016\/j.pharma.2010.04.004_bib83","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1158\/1078-0432.CCR-05-2018","article-title":"CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma","volume":"12","author":"Tse","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pharma.2010.04.004_bib84","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.molonc.2008.02.002","article-title":"Pharmacologically enhanced expression of GPNMB increased the sensitivity of melanoma cells to the CR011-vcMMAE antibody-drug conjugate","volume":"2","author":"Qian","year":"2008","journal-title":"Mol Oncol"}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450910000660?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450910000660?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T23:28:05Z","timestamp":1757719685000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450910000660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7]]},"references-count":84,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["S0003450910000660"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2010.04.004","relation":{},"ISSN":["0003-4509"],"issn-type":[{"value":"0003-4509","type":"print"}],"subject":[],"published":{"date-parts":[[2010,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact actuel des produits naturels sur la d\u00e9couverte de nouveaux m\u00e9dicaments anticanc\u00e9reux","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2010.04.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}